To evaluate its safety, tolerability, pharmacokinetics, and preliminary activity, a phase I/II trial HM‐EMSI‐101 (NCT01588145) 103 was conducted in patients of NSCLC pretreated with EGFR TKI in Korean population (patients were treated with 75‐1 200 mg/day of olmutinib). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.